Last reviewed · How we verify
fatty acids, omega-3
Omega-3 fatty acids reduce triglycerides and modulate inflammatory pathways to improve cardiovascular health.
Omega-3 fatty acids reduce triglycerides and modulate inflammatory pathways to improve cardiovascular health. Used for Hypertriglyceridemia, Cardiovascular disease prevention, Secondary prevention after myocardial infarction.
At a glance
| Generic name | fatty acids, omega-3 |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Lipid-modifying agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Omega-3 polyunsaturated fatty acids (EPA and DHA) decrease hepatic triglyceride synthesis, reduce VLDL production, and inhibit inflammatory mediators including cytokines and eicosanoids. They also improve endothelial function and reduce platelet aggregation, collectively lowering cardiovascular risk.
Approved indications
- Hypertriglyceridemia
- Cardiovascular disease prevention
- Secondary prevention after myocardial infarction
Common side effects
- Gastrointestinal upset
- Fishy aftertaste
- Bleeding (at high doses)
- Nausea
Key clinical trials
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (PHASE2)
- Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia (PHASE2)
- FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) (PHASE2)
- Heart & Health Study (NA)
- NMDA Enhancement Combined With Omega-3 for Early Dementia (PHASE2)
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth (PHASE4)
- Can People Achieve a Target Omega-3 Index by Following a Personalized Omega-3 Dosing Regimen? (NA)
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fatty acids, omega-3 CI brief — competitive landscape report
- fatty acids, omega-3 updates RSS · CI watch RSS
- National Heart, Lung, and Blood Institute (NHLBI) portfolio CI